The Journal of International Medical Research 2011; 39:
|
|
- Bruce Ryan
- 6 years ago
- Views:
Transcription
1 The Journal of International Medical Research 2011; 39: A Randomized, Double-blind Trial of Palonosetron Compared with Ondansetron in Preventing Postoperative Nausea and Vomiting after Gynaecological Laparoscopic Surgery SK PARK AND EJ CHO Department of Anaesthesiology and Pain Medicine, Incheon St Mary s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea This randomized, double-blind study evaluated the relative efficacy of palonosetron (a new, selective 5- hydroxytryptamine type 3 [5-HT 3 ] receptor antagonist) and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing gynaecological laparoscopic surgery. Patients received either palonosetron mg (n = 45) or ondansetron 8 mg (n = 45), intravenously, immediately before induction of general anaesthesia. The occurrence of nausea and vomiting and the severity of nausea according to a visual analogue scale were monitored immediately after the end of surgery and during the following 24 h. The incidence of PONV was significantly lower in the palonosetron group compared with the ondansetron group (42.2% vs 66.7%, respectively). There were no significant statistical differences in the visual analogue scale for nausea. In conclusion, palonosetron mg was more effective than ondansetron 8 mg in preventing PONV. KEY WORDS: PALONOSETRON; ONDANSETRON; 5-HT 3 RECEPTOR ANTAGONIST; POSTOPERATIVE NAUSEA AND VOMITING (PONV); GYNAECOLOGICAL LAPAROSCOPIC SURGERY Introduction Postoperative nausea and vomiting (PONV) is the most common complication of surgery and anaesthesia, 1 leading to adverse consequences including patient dissatisfaction, unexpected hospital admission, and delayed recovery and return to work. 2 PONV is less commonly associated with more serious postsurgical complications such as wound dehiscence and surgical site bleeding. 3 The incidence of PONV can reach 80% in high-risk patients, underlining the importance of prevention and control by anaesthetists. 4 The 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists are popular drugs for PONV prophylaxis because of their similar efficacy to droperidol or dexamethasone and their favourable side-effect profile. 2 Palonosetron is a new, potent, selective 5-HT 3 399
2 receptor antagonist with a strong receptorbinding affinity and a long elimination halflife and, therefore, a long duration of efficacy. 5,6 A study evaluating the efficacy and safety of palonosetron in preventing PONV found that a single mg intravenous (i.v.) dose significantly decreased emetic episodes, nausea severity and rescuemedication use during the first 24 h after anaesthesia, in patients undergoing abdominal or gynaecological laparoscopic surgery. 7 It was also reported that palonosetron is as effective as ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy, 8 although no study has evaluated the relative efficacy of palonosetron and ondansetron in preventing PONV. The present randomized, double-blind study was designed to evaluate the efficacy of palonosetron compared with ondansetron for preventing PONV in patients undergoing laparoscopic gynaecological surgery. Patients and methods PATIENTS Patients who were 21 years old, with American Society of Anesthesiologists physical status 1 or 2, 9 who were scheduled to undergo elective laparoscopic gynaecological surgery of > 1 h duration at Incheon St Mary s Hospital, Incheon, Republic of Korea, between June and September 2010, were randomly enrolled into the study. All the patients enrolled were female and used opioids to control post-operative pain, hence they had at least two risk factors for PONV. Patients were excluded from the study if they had received antiemetics, steroids or psychoactive medications within 24 h of study initiation. Patients with vomiting or retching in the 24 h preceding surgery, those who had received cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry, and patients with ongoing vomiting from gastrointestinal disease were excluded. Study approval was obtained from the Institutional Review Board of Incheon St Mary s Hospital, and all patients provided written informed consent before enrolment. STUDY DESIGN AND TREATMENT Patients were randomized to receive either palonosetron mg or ondansetron 8 mg, administered by i.v. injection. Trained nurses who did not participate in the study prepared the drugs according to manufacturers instructions and placed them in numbered, sealed envelopes assigned by computergenerated random numbers. No patient received preanaesthetic medication. Palonosetron mg was administered in a single i.v. dose, with saline solution added to bring the total volume to 4 ml, immediately before induction of anaesthesia to subjects in the palonosetron group. Subjects in the ondansetron group received ondansetron 8 mg in a single i.v. dose as a 4 ml bolus, immediately before induction of anaesthesia. Standard anaesthetic regimens were used for all patients. Anaesthesia was induced with propofol 2 mg/kg and tracheal intubation was facilitated with rocuronium 0.6 mg/kg. Anaesthesia was maintained with 50% nitrous oxide in oxygen and 1 4% sevoflurane. At the completion of surgery, patients received pyridostigmine 0.2 mg/kg and glycopyrrolate mg/kg, for reversal of neuromuscular blockade. For postoperative pain control, a patientcontrolled anaesthesia device was used to deliver a fentanyl 4 µg bolus with 16 µg/h as background infusion; there was a 15-min lockout time. PATIENT MONITORING The occurrence of nausea and vomiting, the 400
3 severity of nausea according to a visual analogue scale (VAS; 0, no nausea; 10, worst nausea) and rescue antiemetic drug use were monitored immediately after the end of surgery and at 0 2 h, 2 6 h and 6 24 h postsurgery. Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, whereas an episode of vomiting was defined as vomiting (forceful expulsion of gastric contents from the mouth) or retching (laboured, spasmodic, rhythmic contractions of the respiratory muscles without expulsion of gastric contents). 1 Metoclopramide (10 mg i.v.) was permitted as a rescue antiemetic when two episodes of PONV occurred or at VAS > 5 and the patient requested treatment. If metoclopramide treatment was ineffective, ondansetron 4 mg i.v. was permitted. A complete response was defined as the absence of PONV and no use of rescue antiemetics. Details of any adverse effects (including headaches, dizziness, constipation and myalgia) were recorded. Patients were also asked to rate their overall satisfaction on a three-point scale (satisfied, neutral, dissatisfied) 24 h after surgery completion. The primary outcome measure of this study was the incidence of nausea and vomiting during the first 24 h after anaesthesia. Secondary outcome measures were the severity of nausea, need for rescue medication, patient satisfaction and incidence of adverse effects. STATISTICAL ANALYSES Sample size was calculated by a power analysis while designing the study: allowing an α-error of 5% and a β-error of 20%, it was estimated that a minimum of 42 patients per group would be required to show a 30% difference in the incidence of PONV. 7,10 All statistical analyses were performed using SPSS statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows. The Student s t-test was used to compare intergroup differences and the χ 2 or Fisher s exact tests were used for categorical variables. The P-values were corrected by the Bonferroni method and a P-value < 0.05 was regarded as statistically significant. Results In total, 90 patients were recruited, all of whom completed the study. There were no statistically significant differences between palonosetron- and ondansetron-treated groups in terms of patient characteristics, PONV risk factors or operative data (Table 1). The incidence of PONV and nausea (not vomiting) was significantly lower in the palonosetron group than in the ondansetron group during the overall 0 24 h time interval (P < 0.05, Table 2). More patients in the palonosetron group had a complete response (no PONV and no rescue antiemetic) compared with the ondansetron group (Fig. 1); this difference was statistically significant for the 0 24 h time interval (P < 0.05). The severity of nausea (VAS), need for rescue antiemetics, incidence of adverse effects and patient satisfaction ratings were not significantly different between the two groups (Table 3). Discussion A significant proportion of patients experience PONV despite the widespread use of prophylactic antiemetics, including 5-HT 3 receptor antagonists. 11 Ondansetron was the first 5-HT 3 receptor antagonist to be marketed and has frequently been used to control PONV. 12 Palonosetron a secondgeneration 5-HT 3 antagonist has unique structural, pharmacological and clinical properties that distinguish it from other 5- HT 3 antagonists. 2 This is the first study to 401
4 TABLE 1: Baseline demographic data and clinical characteristics for patients undergoing laparoscopic gynaecological surgery who received ondansetron 8 mg or palonosetron mg, intravenously, before anaesthesia Ondansetron group Palonosetron group (n = 45) (n = 45) Age (years) 42.8 ± ± 10.0 Weight (kg) 55.3 ± ± 7.8 Height (cm) ± ± 6.2 ASA PS 1 37 (82.2) 40 (88.9) 2 8 (17.8) 5 (11.1) Risk factors PONV history and/or motion sickness 19 (42.2) 20 (44.4) Non-smoker 43 (95.6) 39 (86.7) Type of surgery Laparoscopic ovarian cystectomy 18 (40.0) 17 (37.8) Laparoscopic hysterectomy 27 (60.0) 28 (62.2) Duration of surgery (min) ± ± 35.3 Duration of anaesthesia (min) ± ± 35.2 Data presented as mean ± SD or n (%) of patients. No statistically significant between-group differences (P > 0.05); Student s t-test and Fisher s exact test. ASA PS, American Society of Anesthesiologists physical status; PONV, postoperative nausea and vomiting. compare palonosetron with ondansetron for PONV. Kovac et al. 7 found that mg palonosetron significantly reduced PONV in the first 24 h after anaesthesia, compared with placebo. In addition, Paventi et al. 13 compared the efficacy of 4 mg versus 8 mg ondansetron for the prevention of PONV after laparoscopic cholecystectomy and concluded that 8 mg was more effective than 4 mg. The doses of drugs used in the present study were based on the optimal dose for prophylaxis of PONV in these previous studies; thus, mg palonosetron and 8 mg ondansetron were chosen. Some investigators have shown that a single i.v. dose of palonosetron 0.25 mg is as safe and effective as ondansetron 32 mg in preventing chemotherapy-induced nausea and vomiting (CINV). 14 The aetiology of CINV, however, primarily involves a large release of serotonin from the enterochromaffin cells in the small intestine in response to chemotherapeutic drugs, 2 whereas the pathophysiology of PONV is more complex and has been suggested to be of multifactorial origin. 15 The incidence of PONV may be associated with many factors including: age and gender (female gender and younger age in adulthood increase the risk of PONV); prior history of motion sickness or PONV; smoking status (smoking decreases the risk of PONV); postoperative opioid use; type and duration of surgery; anaesthesia and ambulation. 1,16,17 These factors were wellbalanced between both treatment groups in the present study. In the present study, palonosteron mg was more effective at reducing PONV than ondansetron 8 mg. This could reflect the high receptor affinity of palonosetron for 5-HT 3, with a low affinity demonstrated for other receptors including 5-HT 1A, 5-HT 1D, 5-HT 2A 402
5 TABLE 2: Incidence of post-operative nausea and vomiting (PONV), need for rescue antiemetics, and severity of PONV in patients undergoing laparoscopic gynaecological surgery who received ondansetron 8 mg or palonosetron mg, intravenously, before anaesthesia Ondansetron group Palonosetron group (n = 45) (n = 45) 0 2 h Nausea 12 (26.7) 4 (8.9) Vomiting 0 (0) 3 (6.7) Overall PONV 12 (26.7) 7 (15.6) VAS 1.5 ± ± h Nausea 10 (22.2) 5 (11.1) Vomiting 3 (6.7) 2 (4.4) Overall PONV 13 (28.9) 7 (15.6) VAS 2.2 ± ± h Nausea 15 (33.3) 9 (20.0) Vomiting 6 (13.3) 4 (8.9) Overall PONV 21 (46.7) 13 (28.9) VAS 3.4 ± ± h Nausea 27 (60.0) 15 (33.3)* Vomiting 7 (15.6) 8 (17.8) Overall PONV 30 (66.7) 19 (42.2)* VAS 4.5 ± ± 4.9 Rescue antiemetics 7 (15.6) 8 (17.8) Data presented as mean ± SD or n (%) of patients. *P < 0.05 for the palonosetron group compared with ondansetron group; Student s t-test and Fisher s exact test. VAS, visual analogue scale for severity of nausea: 0, no nausea; 10, worst nausea. and 5-HT 2C, and the longer duration of action. 5,18 Although palonosetron was superior to ondansetron in reducing overall PONV, the incidence of vomiting was slightly higher (though not statistically significant) in the palonosetron group than in the ondansetron group, possibly due to the stronger antivomiting (rather than antinausea) effect of ondansetron. 19 Ondansetron is significantly superior to metoclopramide and droperidol for the prevention of vomiting, 20 but whether this antiemetic effect is stronger than that of palonosetron is unknown. Several receptor types including serotonin 5-HT 3, dopamine D 2, histamine H 2, α 2 -adrenergic, muscarinic cholinergic, neurokinin 1 and GABA are involved in the initiation and co-ordination of the vomiting reflex in patients with PONV. 15,20 It is possible that palonosetron is less effective than ondansetron at reducing the incidence of vomiting due to the weak binding affinity of ondansetron to 5-HT 1B, 5- HT 1C, α-adrenergic and µ-opioid receptors, 21 although further studies are needed to clarify this issue. The severity of nausea and need for additional rescue antiemetics were not different between the two groups in the present study. The present study showed that patients at moderate or high risk of PONV i.e. who had at least two risk factors for PONV were still 403
6 100 Ondansetron Palonosetron Patients with complete response (%) * Time intervals (h) FIGURE 1: Complete responses (no postoperative nausea and vomiting, no requirement for rescue antiemetic) in patients who underwent laparoscopic gynaecological surgery and received ondansetron 8 mg or palonosetron mg intravenously, before anaesthesia (*P < 0.05 compared with ondansetron group) TABLE 3: Incidence of adverse events and patient satisfaction in patients undergoing laparoscopic gynaecological surgery who received ondansetron 8 mg or palonosetron mg, intravenously, before anaesthesia Ondansetron group Palonosetron group (n = 45) (n = 45) Adverse event Headache 4 (8.9) 3 (6.7) Dizziness 5 (11.1) 5 (11.1) Constipation 2 (4.4) 3 (6.7) Myalgia 0 (0) 1 (2.2) Patient satisfaction Satisfied 21 (46.7) 30 (66.7) Neutral 17 (37.8) 9 (20.0) Dissatisfied 7 (15.6) 6 (13.3) Data presented as n (%) of patients. No statistically significant between-group differences (P > 0.05); χ 2 -test. at high risk for PONV after prophylactic treatment with ondansetron or palonosetron. Thus, patients at moderate or high risk of PONV 4,22 should receive multimodal prophylaxis. 23,24 The potential advantages of combination therapy using drugs that act on 404
7 different pathways in the emetic response include improved efficacy, extended duration of the antiemetic effect, ability to combine drugs with greater antinausea versus greater antiemetic effects and the possibility of using smaller doses of individual drugs compared with monotherapies. 25 In a previous study, a combination of granisetron 3 mg and droperidol 1.25 mg was more effective in the prevention of PONV than either antiemetic alone. 26 Another study found that ondansetron 4 mg plus dexamethasone 8 mg was more effective than ondansetron monotherapy for preventing PONV in patients undergoing laparoscopic cholecystectomy. 27 These results suggest that palonosetron combined with either droperidol or dexamethasone could be an effective combination for the prevention of PONV. Palonosetron mg, i.v. improves the control of nausea and vomiting through the second and third postoperative days. 28 Palonosetron undergoes a slow elimination phase which results in a long half-life of approximately 40 h, in contrast with the 3 5-h half-life of ondansetron, 29 potentially mitigating the higher cost of this newly developed drug, compared with ondansetron. Further trials are necessary to compare the ability of palonosetron and ondansetron to reduce PONV h postoperatively. The 5-HT 3 antagonists have an enviable safety profile, with most side-effects (e.g. headache, constipation, dizziness) being mild and transient. 30,31 Palonosetron has a similar safety profile to other 5-HT 3 antagonists 32 and no difference was found in the incidence of adverse effects between both groups in the present study. There were several limitations to the present study: the efficacies of palonosetron and ondansetron were compared based on the known optimal doses, without knowledge of equipotent doses; the power analysis was performed with the expected incidence of PONV estimated using patients who did not undergo identical types of surgery; and finally, the baseline incidence of PONV was not evaluated by the inclusion of a placebo group because it would be unethical to withhold prophylactic antiemetic drugs in patients at high risk for PONV. In conclusion, palonosetron mg i.v. produced a lower incidence of PONV compared with ondansetron 8 mg i.v. in patients undergoing laparoscopic gynaecological surgery. Conflicts of interest The authors had no conflicts of interest to declare in relation to this article. Received for publication 22 October 2010 Accepted subject to revision 8 November 2010 Revised accepted 25 January 2011 Copyright 2011 Field House Publishing LLP References 1 Watcha MF, White PF: Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: Muchatuta NA, Paech MJ: Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag 2009; 5: Gan TJ: Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102: Apfel CC, Läärä E, Koivuranta M, et al: A simplified risk score for predicting postoperative nausea and vomiting: conclusions from crossvalidations between two centers. Anesthesiology 1999; 91: Wong EH, Clark R, Leung E, et al: The interaction of RS , a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995; 114:
8 6 Stoltz R, Cyong JC, Shah A, et al: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44: Kovac AL, Eberhart L, Kotarski J, et al: A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72- hour period. Anesth Analg 2008; 107: Aapro MS, Grunberg SM, Manikhas GM, et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: Sweitzer BJ: Overview of preoperative assessment and management. In: Anesthesiology (Longnecker DE, ed.). Columbus: McGraw-Hill, 2008; pp Yun MJ, Kim YH, Kim AR: Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery. Yonsei Med J 2010; 51: Gupta A, Wu CL, Elkassabany N, et al: Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?: A systematic review of randomized controlled trials. Anesthesiology 2003; 99: Habib AS, Gan TJ: Evidence-based management of postoperative nausea and vomiting: a review. Can J Anesth 2004; 51: Paventi S, Santevecchi A, Ranieri R: Efficacy of a single-dose ondansetron for preventing postoperative nausea and vomiting after laparoscopic cholecystectomy with sevoflurane and remifentanil infusion anaesthesia. Eur Rev Med Pharmacol Sci 2001; 5: Gralla R, Lichinitser M, Van Der Vegt S, et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: Kovac AL: Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59: Koivuranta M, Ala-Kokko TI, Jokela R, et al: Comparison of ondansetron and tropisetron combined with droperidol for the prevention of emesis in women with a history of postoperative nausea and vomiting. Eur J Anaesthesiol 1999; 16: Sinclair DR, Chung F, Mezei G: Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91: Newberry NR, Watkins CJ, Sprosen TS, et al: BRL potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 1993; 32: Tramer MR, Reynolds DJ, Moore RA, et al: Efficacy, dose response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebocontrolled trials. Anesthesiology 1997; 87: Gan TJ: Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007; 21: Kovac AL: Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists. J Clin Anesth 2006; 18: Apfel CC, Kranke P, Eberhart LH, et al: Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2000; 88: Scuderi PE, James RL, Harris L, et al: Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000; 91: Paech MJ, Lee BH, Evans SF: The effect of anaesthetic technique on postoperative nausea and vomiting after day-case gynaecological laparoscopy. Anaesth Intensive Care 2002; 30: Gan TJ, Coop A, Philip BK, et al: A randomized, double-blind study of granisetron plus dexamethasone versus ondansetron plus dexamethasone to prevent postoperative nausea and vomiting in patients undergoing abdominal hysterectomy. Anesth Analg 2005; 101: Fujii Y, Saitoh Y, Tanaka H, et al: Prophylactic antiemetic therapy with granisetron droperidol combination in patients undergoing laparoscopic cholecystectomy. Can J Anaesth 1998; 45: Elhakim M, Nafie M, Mahmoud K, et al: Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 2002; 49: Candiotti KA, Kovac AL, Melson TI, et al: A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008; 107: Stoltz R, Parisi S, Shah A, et al: Pharmacokinetics, metabolism and excretion 406
9 of intravenous [ 14 C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004; 25: Leslie JB, Gan TJ: Meta-analysis of the safety of 5-HT 3 antagonists with dexamethasone or droperidol for prevention of PONV. Ann Pharmacother 2006; 40: Ho KY, Gan TJ: Pharmacology, pharmacogenetics, and clinical efficacy of 5- hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006; 19: Navari RM: Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol 2009; 12: Author s address for correspondence Associate Professor Eun Jung Cho Department of Anaesthesiology and Pain Medicine, Incheon St Mary s Hospital, College of Medicine, The Catholic University of Korea, Bupyeong 6 dong, Bupyeonggu, Incheon , Republic of Korea. gkjw2000@catholic.ac.kr 407
Palonosetron vs Ondansetron for prevention of postoperative nausea and vomiting in...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. XI (Feb. 2016), PP 45-49 www.iosrjournals.org Palonosetron vs Ondansetron for prevention
More informationEfficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial
British Journal of Anaesthesia 112 (3): 485 90 (2014) Advance Access publication 22 October 2013. doi:10.1093/bja/aet340 CLINICAL PRACTICE Efficacy of palonosetron for the prevention of postoperative nausea
More informationDEXAMETHASONE WITH EITHER GRANISETRON OR ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERY
DEXAMETHASONE WITH EITHER GRANISETRON OR ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERY Alia S. Dabbous *, Samar I. Jabbour-Khoury **, Viviane G Nasr ***, Adib A Moussa ***,
More informationEfficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting
European Review for Medical and Pharmacological Sciences 2001; 5: 59-63 Efficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting after laparoscopic cholecystectomy with sevoflurane
More informationIJMDS January 2017; 6(1) Dr Robina Makker Associate professor 2 Dr Amit Bhardwaj
Original Article Comparative efficacy of ondansetron versus granisetron to prevent perioperative nausea and vomiting in patients undergoing gynaecological surgery under spinal anaesthesia Makker R 1, Bhardwaj
More informationDexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy
Original Research Article Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy T. Uma Maheswara Rao * Associate Professor, Department of Surgery, Konaseema Institute
More informationPost-operative nausea and vomiting after gynecologic laparoscopic surgery: comparison between propofol and sevoflurane
Clinical Research Article Korean J Anesthesiol 2011 January 60(1): 36-40 DOI: 10.4097/kjae.2011.60.1.36 Post-operative nausea and vomiting after gynecologic laparoscopic surgery: comparison between propofol
More informationManagement of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem
Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Mary Keyes, MD KEYWORDS Postoperative nausea and vomiting PONV prophylaxis PONV in ambulatory surgery KEY POINTS
More informationPostoperative nausea and vomiting prophylaxis: The efficacy of a novel antiemetic drug (palonosetron) combined with dexamethasone
Egyptian Journal of Anaesthesia (2013) 29, 117 123 Egyptian Society of Anesthesiologists Egyptian Journal of Anaesthesia www.elsevier.com/locate/egja www.sciencedirect.com Research Article Postoperative
More informationDroperidol has comparable clinical efficacy against both nausea and vomiting
British Journal of Anaesthesia 103 (3): 359 63 (2009) doi:10.1093/bja/aep177 Advance Access publication July 15, 2009 has comparable clinical efficacy against both nausea and vomiting C. C. Apfel 1 *,
More informationISSN X (Print) India. *Corresponding author Dr. D. Shiva Prasad
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(9C):3311-3315 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationJ Med Assoc Thai 2016; 99 (5): Full text. e-journal:
A Randomized Placebo-Controlled Trial of Oral Ramosetron for Prevention of Post Operative Nausea and Vomiting after Intrathecal Morphine in Patients Undergoing Gynecological Surgery Suratsawadee Wangnamthip
More informationIs Intravenous Ramosetron 0.3 mg Effective In The Prevention Of Postoperative Nausea And Vomiting In Women Undergoing Gynecologic Surgery?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Intravenous Ramosetron 0.3 mg Effective
More informationDhawal R. Wadaskar*, Jyoti S. Magar, Bharati A. Tendolkar
International Journal of Research in Medical Sciences Wadaskar DR et al. Int J Res Med Sci. 2016 Aug;4(8):3191-3197 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162214
More informationAntiemetic in Caesarean section under spinal anaesthesia: new option
IOSR Journal of Pharmacy and Biological Sciences (IOSRJPBS) ISSN : 2278-3008 Volume 3, Issue 2 (Sep-Oct 2012), PP 01-05 Antiemetic in Caesarean section under spinal : new option Balaram Ghosh 1, Suman
More informationJMSCR Vol 07 Issue 04 Page April 2019
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i4.76 A study to compare the antiemetic efficacy of ondansetron
More informationEfficacy of Prophylactic Ondansetron in a Patient-controlled Analgesia Environment
The Journal of International Medical Research 2004; 32: 160 165 Efficacy of Prophylactic Ondansetron in a Patient-controlled Analgesia Environment SH HAN, YJ LIM, YJ RO, SC LEE, YS PARK AND YC KIM Department
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr COMPARISON OF ONDANSETRON V/S RAMOSETRON FOR PREVENTION OF POST OPERATIVE
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161869 Research Article Ondansetron versus palonosetron:
More informationLow-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting
Low-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting John D. Bridges, BS (Pharm)* Cindy B. Nettle, PharmD* Vijaya J. Dugirrala MD Katie J. Suda, PharmD Kevin W. Garey, PharmD *Baptist
More informationPre-medication with controlled-release oxycodone in the management of postoperative pain after ambulatory laparoscopic gynaecological surgery
Page 1 of 5 Anaesthetics & Critical Care Pre-medication with controlled-release oxycodone in the management of postoperative pain after ambulatory laparoscopic gynaecological surgery B Lim 1, SY Thong
More informationClinical Study Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients
BioMed Research International Volume 2015, Article ID 951474, 6 pages http://dx.doi.org/10.1155/2015/951474 Clinical Study Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting
More informationNausea and vomiting after surgery
Sébastien Pierre MD Rachel Whelan Matrix reference 1A02 Key points 5-Hydroxytrytamine type 3 (5-HT 3 ) receptor antagonists, and specifically ondansetron, are the most commonly used antiemetics for both
More informationWon-Suk Lee 1, Kwang-Beom Lee 2, Soyi Lim 2 and Young Gin Chang 3*
Lee et al. BMC Anesthesiology (2015) 15:121 DOI 10.1186/s12871-015-0102-0 RESEARCH ARTICLE Open Access Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea
More informationAlizaprideand ondansetronin the prevention of postoperative nausea and vomiting: a prospective, randomized, double-blind, placebocontrolled
Alizaprideand ondansetronin the prevention of postoperative nausea and vomiting: a prospective, randomized, double-blind, placebocontrolled trial. M. Smets N. Van Langenhove G. Dewinter Vrijdagochtendkrans22
More informationEditor s key points. M. S. Green*, P. Green, S. N. Malayaman, M. Hepler, L. J. Neubert and J. C. Horrow
British Journal of Anaesthesia 109 (5): 716 22 (2012) Advance Access publication 24 July 2012. doi:10.1093/bja/aes233 Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant
More informationClinical Research INTRODUCTION. Gwieun Yeo 1, Mi Kyoung Lee 1, Heezoo Kim 1, Myounghoon Kong 1, Hyo Jung Son 2, and Han Byeol Oh 2
Anesth Pain Med 2018;13:256-263 https://doi.org/10.17085/apm.2018.13.3.256 pissn 1975-5171 ㆍ eissn 2383-7977 Clinical Research Received November 17, 2017 Revised 1st, January 29, 2018 2nd, March 15, 2018
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationA Cross Sectional Study on Postoperative Nausea and Vomiting Risk Prediction and Assessment in Patients Undergoing Elective Surgical Patients
ORIGINAL RESEARCH www.ijcmr.com A Cross Sectional Study on Postoperative Nausea and Vomiting Risk Prediction and Assessment in Patients Undergoing Elective Surgical Patients Anu Karthiga Manoharan 1, Nazir
More informationAntiemetic Effect Of Propofol Administered At The End Of Surgery
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 11 Ver. III (November. 2016), PP 54-58 www.iosrjournals.org Antiemetic Effect Of Propofol Administered
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationComparison of Drugs and Intravenous Crystalloid in Reduction of Postoperative Nausea and Vomiting after Laparoscopic Surgery
Comparison of Drugs and World Intravenous Journal of Crystalloid Laparoscopic in Reduction Surgery, of January-April Postoperative 2008;1(1):29-34 Nausea and Vomiting after Lap Surgery Comparison of Drugs
More informationReceived: 29/05/2017 Revised: 11/09/2017 Accepted: 26/07/2017 ABSTRACT
International Journal of Medical Science and Education An official Publication of Association for Scientific and Medical Education (ASME) Original research Article PREOPERATIVE PALONOSETRON AND DEXAMETHASONE
More informationCOMPARISON OF INDUCTION WITH SEVOFLURANE-FENTANYL AND PROPOFOL-FENTANYL ON POSTOPERATIVE NAUSEA AND VOMITING AFTER LAPAROSCOPIC SURGERY
RESEARCH ARTICLE COMPARISON OF INDUCTION WITH SEVOFLURANE-FENTANYL AND PROPOFOL-FENTANYL ON POSTOPERATIVE NAUSEA AND VOMITING AFTER LAPAROSCOPIC SURGERY ABSTRACT Ghanta.V. Nalini Kumari 1,*, Sushma Ladi
More informationNew Drugs in Pediatric Anesthesia
New Drugs in Pediatric Anesthesia Anne M. Lynn MD Seattle Children s Hospital University of Washington School of Medicine There s nothing like a nice, focused topic to start this meeting. So many drugs,
More informationOndansetron, a selective blocking agent of the. Timing of ondansetron administration to prevent postoperative nausea and vomiting
Timing of ondansetron administration to prevent postoperative nausea and vomiting NORMA I. CRUZ, MD*; PETER PORTILLA, MD ; ROSENDO E. VELA, MD Background: The original guidelines for using ondansetron
More informationEun Jin Ahn, 1 Geun Joo Choi, 2 Hyun Kang, 2 Chong Wha Baek, 2 Yong Hun Jung, 2 and Young Cheol Woo Introduction. 2. Materials and Methods
Hindawi BioMed Research International Volume 2017, Article ID 9341738, 6 pages https://doi.org/10.1155/2017/9341738 Research Article Comparison of Ramosetron with Palonosetron for Prevention of Postoperative
More informationEffects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery
Clinical Report Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery Journal of International Medical Research 2018, Vol. 46(1) 411 420! The Author(s) 2017
More informationManagement of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes 1^
British Journal of Anaesthesia 89 (3): 473-8 (2002) Management of post-strabismus nausea and vomiting in children using ondansetron: a value-based comparison of outcomes 1^ B. Sennaraj 1, D. Shende 1,
More informationThe Incidence of Postoperative Nausea and Vomiting after Thyroidectomy using Three Anaesthetic Techniques
The Journal of International Medical Research 2011; 39: 1834 1842 The Incidence of Postoperative Nausea and Vomiting after Thyroidectomy using Three Anaesthetic Techniques YJ WON 1, JY YOO 2, YJ CHAE 1,
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationAntiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous patient-controlled analgesia
British Journal of Anaesthesia 94 (6): 835 9 (2005) doi:10.1093/bja/aei137 Advance Access publication April 15, 2005 Antiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous
More informationPalonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study
Candiotti et al. BMC Pharmacology and Toxicology 2014, 15:45 http://www.biomedcentral.com/2050-6511/15/45 RESEARCH ARTICLE Open Access Palonosetron versus ondansetron as rescue medication for postoperative
More informationSection: Anaesthesia. Original Article INTRODUCTION
DOI: 10.21276/aimdr.2017.3.3.AN8 Original Article ISSN (O):2395-2822; ISSN (P):2395-2814 Comparison of Granisetron, Palonosetron and Ondansetron for Prevention of Postoperative Nausea and Vomiting in Gynaecological
More informationAntiemetic Prophylaxis for Office-based Surgery
CLINICAL INVESTIGATIONS Anesthesiology 2003; 98:293 8 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Antiemetic Prophylaxis for Office-based Surgery Are the 5-HT 3
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationPostoperative nausea and vomiting
original article Oman Medical Journal [2015], Vol. 30, No. 4: 252 256 Postoperative Nausea and Vomiting: Palonosetron with Dexamethasone vs. Ondansetron with Dexamethasone in Laparoscopic Hysterectomies
More informationIs lorazepam effective at preventing nausea and vomiting after laparoscopic cholecystectomy? A randomized controlled trial
(Acta Anaesth. Belg., 2017, 68, 131-135) Is lorazepam effective at preventing nausea and vomiting after laparoscopic cholecystectomy? A randomized controlled trial F. Javaherforoosh Zadeh (*), A. Ghomeishi
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationComparison of surgical site and patient s history with a simplified risk score for the prediction of postoperative nausea and vomiting
Comparison of surgical site and patient s history with a simplified risk score for the prediction of postoperative nausea and vomiting C. C. Apfel, 1,2 P. Kranke 2 and L. H. J. Eberhart 3 1 Department
More informationLOW DOSE INTRAVENOUS MIDAZOLAM FOR PREVENTION OF PONV, IN LOWER ABDOMINAL SURGERY
LOW DOSE INTRAVENOUS MIDAZOLAM FOR PREVENTION OF PONV, IN LOWER ABDOMINAL SURGERY - Preoperative vs Intraoperative Administration - Mohammad Reza Safavi * and Azim Honarmand ** Abstract Background: The
More informationThe Comparison Effect of Preoperative Ondansetron and Metoclopramide in Reducing Nausea and Vomitting after Loparoscopic Cholecystectomy
Journal of Ardabil University of Medical Sciences Vol.3, No.2, Summer 203, Pages 55-63 The Comparison Effect of Preoperative Ondansetron and Metoclopramide in Reducing Nausea and Vomitting after Loparoscopic
More informationA comparative study of the antiemetic efficacy of dexamethasone, ondansetron, and metoclopramide in patients undergoing gynecological surgery
Med Sci Monit, 2010; 16(7): CR336-341 PMID: 20581776 WWW.MEDSCIMONIT.COM Clinical Research Received: 2008.04.25 Accepted: 2009.05.31 Published: 2010.07.01 A comparative study of the antiemetic efficacy
More informationX.-Y. Yang 1, J. Xiao 2, Y.-H. Chen 2, Z.-T. Wang 2, H.-L. Wang 1, D.-H. He 2 and J. Zhang 1,2, * Abstract
British Journal of Anaesthesia, 115 (6): 883 9 (2015) doi: 10.1093/bja/aev352 Advance Access Publication Date: 27 October 2015 Clinical Practice Dexamethasone alone vs in combination with transcutaneous
More informationMeasure Abbreviation: PONV 01 (MIPS 430)
Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination
More informationORIGINALARTICLE. Semira*, Zaffar Abbas*, Vishal R.Tandon**, Amina Bashir*, Kirpal Kour*** Introduction JK SCIENCE
ORIGINALARTICLE A Prospective, Randomized, Placebo-Controlled, Trial Comparing the Effectiveness of Gabapentin, Ondansetron & Dexamethasone in Prevention of Nausea &Vomiting after Laparoscopic Cholecystectomy
More informationGastrointestinal and urinary complications in the postoperative period
The 13 th Annual Perioperative Medicine Summit Fort Lauderdale, Florida Gastrointestinal and urinary complications in the postoperative period Dan Hunt, MD Professor of Medicine Director, Division of Hospital
More informationBreast Augmentation: Reducing Postoperative Nausea and Vomiting. A Prospective Study
Journal of Anesthesia & Critical Care: Open Access Breast Augmentation: Reducing Postoperative and. A Prospective Abstract Background: Breast augmentation is the plastic surgery procedure associated with
More informationKEYWORDS Obstetric Patient, Spinal Anesthesia, PONV (Post-Operative Nausea and Vomiting), Inj. Metoclopramide, Inj. Ondansetron.
PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN ELECTIVE LSCS UNDER SPINAL ANAESTHESIA BY PRE-OPERATIVE ONDANSETRON VERSUS METOCLOPRAMIDE: A PROSPECTIVE SINGLE-BLINDED RANDOMISED CONTROL TRIAL Prasada
More informationV. Nesek-Adam, 1 E. Grizelj-Stojcˇic, 1 Zˇ. Rasˇic, 2 Z. Cˇala, 2 V. Mrsˇic, 1 A. Smiljanić 1
Surg Endosc (2007) DOI: 10.1007/s00464-006-9122-7 Ó Springer Science+Business Media, Inc. 2007 Comparison of dexamethasone, metoclopramide, and their combination in the prevention of postoperative nausea
More informationISPUB.COM. A Wadaskar, N Swarnkar, A Yadav INTRODUCTION METHODS
ISPUB.COM The Internet Journal of Anesthesiology Volume 20 Number 1 Granisetron has superior control over postoperative nausea and vomiting than ondansetron in gynecological surgeries: a placebo controlled
More information4/18/2018. Disclosure. Learning Objectives. St. Vincent Healthcare. Supportive Literature. Background
Implementation of a risk-score-dependent antiemetic protocol to reduce post-operative nausea and vomiting (PONV) in inpatient surgical patients Eugene P. Eldridge, PharmD, RPh PGY-1 Pharmacy Resident St.
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationJ. Basic. Appl. Sci. Res., 2(9) , , TextRoad Publication
2012, TextRoad Publication ISSN 2090-4304 Journal of Basic and Applied Scientific Research www.textroad.com The Evaluation of Post Spinal Anesthesia Nausea and Vomiting Incidence with Lidocaine Versus
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationDrug Class Review on Newer Antiemetics
Drug Class Review on Newer Antiemetics Final Report January 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative
More informationThe effect of duration of dose delivery with patient-controlled analgesia on the incidence of nausea and vomiting after hysterectomy
Br J Clin Pharmacol 1998; 45: 57 62 The effect of duration of dose delivery with patient-controlled analgesia on the incidence of nausea and vomiting after hysterectomy Annie Woodhouse* & Laurence E. Mather
More informationMeasure Abbreviation: PONV 01 (MIPS 430)
Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationPONV in Ambulatory surgery: A comparison between Ramosetron and Ondansetron: a prospective, double-blinded, and randomized controlled study
ORIGINAL ARTICLE Page 25 PONV in Ambulatory surgery: A comparison between and Ondansetron: a prospective, double-blinded, and randomized controlled study Debasis Banerjee, Anjan Das 1, Saikat Majumdar
More informationReply to the Joint Editors-in-Chief Request for Determination Regarding Papers Published by Dr. Yoshitaka Fujii, dated April 9, 2012
Reply to the Joint Editors-in-Chief Request for Determination Regarding Papers Published by Dr. Yoshitaka Fujii, dated April 9, 2012 December 26, 2012 Research Integration Committee, University of Tsukuba
More informationPage 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories
Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS risk factors from the categories listed below more than one drug prophylaxis (see Appendix A for antiemetic choices) Patient scheduled for surgery Assess patient
More informationOriginal Article Antiemetics in Prolong Surgeries Pak Armed Forces Med J 2015; 65(3):353-57
Original Article Antiemetics in Prolong Surgeries Pak Armed Forces Med J 2015; 65(3):353-57 POST OPERATIVE NAUSEA AND VOMITING [PONV]: COMPARISON OF TIMING OF ADMINISTRATION OF ANTIEMETICS IN PROLONG SURGERIES
More informationSaeyoung Kim 1, Younghoon Jeon 2, Hyeonjun Lee 1, Jung A Lim 1, Sungsik Park 1, Si Oh Kim 1 INTRODUCTION. Original Article
Original Article pissn 2383-9309 eissn 2383-9317 J Dent Anesth Pain Med 2016;16(4):289-294 https://doi.org/10.17245/jdapm.2016.16.4.289 The evaluation of implementing smart patient controlled analgesic
More informationEffects of IV Ondansetron during spinal anaesthesia with Ropivacaine and Fentanyl
Original article Effects of IV Ondansetron during spinal anaesthesia with Ropivacaine and Fentanyl 1Dr Bipul Deka, 2 Dr Bharat Talukdar, 3 Dr. Amal Kumar Laha, 4 Dr. Rupak Bhattacharjee 1Assistant Professor,
More informationMaterials and Methods
Anesthesiology 2002; 97:1075 81 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Comparative Efficacy of Acustimulation (ReliefBand ) versus Ondansetron (Zofran ) in
More informationResearch Article. Shital S. Ahire 1 *, Shweta Mhambrey 1, Sambharana Nayak 2. Received: 22 July 2016 Accepted: 08 August 2016
International Journal of Research in Medical Sciences Ahire SS et al. Int J Res Med Sci. 2016 Sep;4(9):3838-3844 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162824
More informationReexamining Metoclopramide s Role in the Prevention of Postoperative Nausea and Vomiting: A Secondary Analysis
Reexamining Metoclopramide s Role in the Prevention of Postoperative Nausea and Vomiting: A Secondary Analysis Amy J. Masiongale, DNP, CRNA Jane T. Garvin, PhD, RN, FNP-BC Marguerite J. Murphy, DNP, RN
More informationEfficacy Of Propofol In Preventing Postoperative Nausea And Vomiting (PONV): Single Blind Randomized Control Study
ISPUB.COM The Internet Journal of Anesthesiology Volume 7 Number 1 Efficacy Of Propofol In Preventing Postoperative Nausea And Vomiting (PONV): Single Blind Randomized Control Study Ramanathan, Augustus,
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 PRODUCT NAME TROPISETRON-AFT tropisetron hydrochloride (equivalent to 2 mg or 5 mg tropisetron) per ampoule. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg of tropisetron 1 2 ml ampoule
More informationDexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery
Article ID: WMC002013 2046-1690 Dexamethasone Compared with Metoclopramide in Prevention of Postoperative Nausea and Vomiting in Orthognathic Surgery Corresponding Author: Dr. Agreta Gashi, Anesthesiologist,
More informationIncidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan
J Anesth (2013) 27:18 24 DOI 10.1007/s00540-012-1468-5 ORIGINAL ARTICLE Incidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan
More informationCOBISS.SR-ID EFFECTIVNESS OF DEXAMETASONE VS. MAGNESIUM SULPHATE IN POSTOPERA- TIVE ANALGESIA (DEXAMETASONE VS. MAGNESIUM SULPHATE)
COBISS.SR-ID 222299404 616-089.5-06:616.33-008.3 615.243.6 Original article EFFECTIVNESS OF DEXAMETASONE VS. MAGNESIUM SULPHATE IN POSTOPERA- TIVE ANALGESIA (DEXAMETASONE VS. MAGNESIUM SULPHATE) Brikena
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationPalonosetron Hydrochloride in the Prevention and Treatment of Postoperative Nausea and Vomiting
Clinical Medicine Insights: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Palonosetron ydrochloride in the Prevention and Treatment
More informationNQS Domain: Patient Safety. Measure Type: Process
Measure Abbreviation: PONV 02 (MIPS 463) *PONV 02 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 463: Prevention of Post-Operative Vomiting (POV) Combination Therapy
More informationRemifentanil. Addressing the challenges of ambulatory orthopedic procedures 1-3
Remifentanil Addressing the challenges of ambulatory orthopedic procedures 1-3 INDICATIONS AND IMPORTANT RISK INFORMATION INDICATIONS ULTIVA (remifentanil HCl) for Injection is indicated for intravenous
More informationA Comparative Clinical Study Of Prevention Of PostOperative Nausea And Vomiting Using Granisetron And
ISPUB.COM The Internet Journal of Anesthesiology Volume 26 Number 1 A Comparative Clinical Study Of Prevention Of PostOperative Nausea And Vomiting Using Granisetron And Ondansetron In Laparoscopic Surgeries.
More informationOriginal Article. Abstract. Introduction. KU Tobi, CO Imarengiaye, FE Amadasun. Key words: Antiemetic, myomectomy, spinal anaesthesia
Original Article The effects of dexamethasone and metoclopramide on early and late postoperative nausea and vomiting in women undergoing myomectomy under spinal anaesthesia KU Tobi, CO Imarengiaye, FE
More informationEffect of Intraoperative Dextrose Infusion for Prevention of Postoperative Nausea and Vomiting in Diagnostic Gynecologic Laparoscopy
http://www.cjmb.org Open Access Original Article Crescent Journal of Medical and Biological Sciences Vol. 5, No. 1, January 2018, 45 49 eissn 2148-9696 Effect of Intraoperative Dextrose Infusion for Prevention
More informationEvaluation of Postoperative Complications Occurring in Patients after Desflurane or Sevoflurane in Outpatient Anaesthesia: A Comparative Study
Original article Evaluation of Postoperative Complications Occurring in Patients after Desflurane or Sevoflurane in Outpatient Anaesthesia: A Comparative Study Shishir Ramachandra Sonkusale 1, RajulSubhash
More informationThe Sparing Effect of Low-dose Esmolol on Sevoflurane during Laparoscopic Gynaecological Surgery
The Journal of International Medical Research 2011; 39: 1861 1869 [first published online as 39(5) 4] The Sparing Effect of Low-dose Esmolol on Sevoflurane during Laparoscopic Gynaecological Surgery YE
More informationAntiemetic Prophylaxis with Ondansetron or Granisetron in Patients Undergoing Laparoscopic Cholecystectomy
Antiemetic Prophylaxis with Ondansetron or Granisetron in Patients Undergoing Laparoscopic Cholecystectomy Dr. Tarek M. Esmael MD, Dr. Noha M. Ibrahim MD, Dr.Ehab M Mokbel MD. From Departments of General
More informationProphylactic use of dexamethasone in tonsillectomy among children
Prophylactic use of dexamethasone in tonsillectomy among children Author(s): Ali Maeed Al-Shehri Vol. 11, No. 1 (2007-10 - 2007-12) Curr Pediatr Res 2007; 11 (1 & 2): 3-7 Ali Maeed Al-Shehri Department
More informationPostoperative Nausea and Vomiting: Update on Prevention, Rescue, and Novel Strategies
Postoperative Nausea and Vomiting: Update on Prevention, Rescue, and Novel Strategies No conflicts of interest to disclose (sadly) 2 March 2016 Melissa Brooks Peterson, MD Department of Anesthesiology/Pediatric
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationEvaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure
British Journal of Anaesthesia 88 (6): 819±23 (2002) Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure D. Song, F. Chung*,
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More information